{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Best response is defined as the cumulative numbers of participants who achieve each level of best response including complete response (CR), partial response (PR), Stable Disease (SD), and Progressive Disease (PD) after treatment. Best response was assessed by the antitumor response criteria.","groups":[{"description":"Adult participants with adult T-cell leukemia/lymphoma (ATLL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"OG000","title":"Adult Participants With ATLL"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy analysis set: all participants who received at least one dose of protocol treatment without major protocol deviation. The number analyzed was the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to 12 Months","title":"Percentage of Participants Who Achieve or Maintain Any Best Response for Adult Participants With ATLL","type":"SECONDARY","unitOfMeasure":"Participants"}